Ftse Mib
38.327,72
0,92%
DAX
22.798,09
1,40%
S&P 500
6.114,63
-0,01%
NASDAQ
20.026,77
0,41%
Bitcoin
95.839,96
0,07%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Y mAbs Therapeutics Inc (YMAB) Y mAbs Therapeutics Inc (YMAB) Notizie

YMAB

Y mAbs Therapeutics (YMAB)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:YMAB
DataOraFonteTitoloSimboloCompagnia
06/02/202513:30GlobeNewswire Inc.Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences ConferenceNASDAQ:YMABY mAbs Therapeutics Inc
31/01/202513:35GlobeNewswire Inc.Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual MeetingNASDAQ:YMABY mAbs Therapeutics Inc
23/01/202501:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
17/01/202522:18Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
13/01/202515:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:YMABY mAbs Therapeutics Inc
10/01/202515:26GlobeNewswire Inc.Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 PrioritiesNASDAQ:YMABY mAbs Therapeutics Inc
10/01/202513:35GlobeNewswire Inc.Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business UnitNASDAQ:YMABY mAbs Therapeutics Inc
10/01/202513:05GlobeNewswire Inc.Y-mAbs Provides Strategic Business Update and 2025 PrioritiesNASDAQ:YMABY mAbs Therapeutics Inc
23/12/202413:30GlobeNewswire Inc.Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:YMABY mAbs Therapeutics Inc
07/12/202418:00GlobeNewswire Inc.Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual MeetingNASDAQ:YMABY mAbs Therapeutics Inc
27/11/202413:35GlobeNewswire Inc.Y-mAbs to Participate at Citi’s 2024 Global Healthcare ConferenceNASDAQ:YMABY mAbs Therapeutics Inc
14/11/202422:32Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:YMABY mAbs Therapeutics Inc
08/11/202413:18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:YMABY mAbs Therapeutics Inc
08/11/202412:35GlobeNewswire Inc.Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate DevelopmentsNASDAQ:YMABY mAbs Therapeutics Inc
04/11/202413:35GlobeNewswire Inc.Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in JapanNASDAQ:YMABY mAbs Therapeutics Inc
25/10/202413:05GlobeNewswire Inc.Y-mAbs Announces Third Quarter 2024 Conference Call and WebcastNASDAQ:YMABY mAbs Therapeutics Inc
01/10/202413:05GlobeNewswire Inc.Y-mAbs to Participate in Upcoming Investor Conferences in OctoberNASDAQ:YMABY mAbs Therapeutics Inc
13/09/202422:19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
06/09/202413:30GlobeNewswire Inc.Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer ResearchNASDAQ:YMABY mAbs Therapeutics Inc
03/09/202414:32GlobeNewswire Inc.Y-mAbs to Participate in Upcoming Investor Conferences in SeptemberNASDAQ:YMABY mAbs Therapeutics Inc
12/08/202412:30GlobeNewswire Inc.Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate DevelopmentsNASDAQ:YMABY mAbs Therapeutics Inc
07/08/202413:05GlobeNewswire Inc.Y-mAbs to Participate in Upcoming Investor Conferences in AugustNASDAQ:YMABY mAbs Therapeutics Inc
05/08/202422:05GlobeNewswire Inc.Y-mAbs Announces Second Quarter 2024 Conference Call and WebcastNASDAQ:YMABY mAbs Therapeutics Inc
01/07/202422:05GlobeNewswire Inc.Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial OfficerNASDAQ:YMABY mAbs Therapeutics Inc
07/06/202413:05GlobeNewswire Inc.Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual MeetingNASDAQ:YMABY mAbs Therapeutics Inc
05/06/202413:05GlobeNewswire Inc.Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development OfficerNASDAQ:YMABY mAbs Therapeutics Inc
01/06/202414:15GlobeNewswire Inc.Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual MeetingNASDAQ:YMABY mAbs Therapeutics Inc
01/06/202414:05GlobeNewswire Inc.Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual MeetingNASDAQ:YMABY mAbs Therapeutics Inc
07/05/202422:05GlobeNewswire Inc.Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate DevelopmentsNASDAQ:YMABY mAbs Therapeutics Inc
26/04/202413:05GlobeNewswire Inc.Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024NASDAQ:YMABY mAbs Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:YMAB

La tua Cronologia

BIT
UC8MSK
Unicredit Bank
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci